<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375358</url>
  </required_header>
  <id_info>
    <org_study_id>NGUYEN 2018</org_study_id>
    <nct_id>NCT04375358</nct_id>
  </id_info>
  <brief_title>Creatinine Clearance as a Predictor of Successful Withdrawl of Continuous Renal Replacement Therapy in Intensive Care</brief_title>
  <acronym>STOP EERc</acronym>
  <official_title>Creatinine Clearance as a Predictor of Successful Withdrawl of Continuous Renal Replacement Therapy in Intensive Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute renal failure is a common complication in patients admitted to intensive care. Due to&#xD;
      the increasing incidence of acute renal failure, the use of Continuous Renal Replacement&#xD;
      Therapy (CRRT) is on the rise in the intensive care unit. The use of CRRT exposes patients to&#xD;
      some complications (bleeding, hemodynamic instability, antibiotic underdosing, malnutrition&#xD;
      and infections), justifying the importance of optimizing the quality and reliability of this&#xD;
      technique. Renal function is classically assessed by diuresis and creatinine. Creatinine&#xD;
      clearance is an indirect measure of glomerular filtration rate. Measuring creatinine&#xD;
      clearance is a simple, accessible and relatively inexpensive method. Traditionally,&#xD;
      clreatinine clearance has required 24-hour urine collection. However, it has been shown that&#xD;
      two-hour urine collection is also an accurate tool.&#xD;
&#xD;
      There is little information and few recommendations as to when to discontinue CRRT. A&#xD;
      predictive index for the withdrawal of CRRT would reduce the duration of treatment, reduce&#xD;
      complications and costs, and speed up patient rehabilitation.&#xD;
&#xD;
      Various parameters have been described as tools for deciding when to stop dialysis: diuresis&#xD;
      before stopping CRRT, urine and blood creatinine, daily urinary urea excretion, and sodium&#xD;
      and water balance. Among these factors, urine output and creatinine appear to be promising&#xD;
      predictive factors. The measurement of creatinine clearance combines these two factors and&#xD;
      can therefore be a good tool for predicting the return of adequate renal function.&#xD;
      Retrospective work carried out by Fr√∂hlich et al in 2012 suggested that creatinine clearance&#xD;
      measured over 2 hours could be a good marker for successful withdrawal.&#xD;
&#xD;
      The hypothesis of the study is that creatinine clearance measured over 2 hours after stopping&#xD;
      CRRT is be predictive of the success of the withdrawal from this type of therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>creatinine clearance over 2 hours</measure>
    <time_frame>Through study completion, an average of 2 hours</time_frame>
  </primary_outcome>
  <enrollment type="Actual">64</enrollment>
  <condition>Dialysis Withdrawal</condition>
  <condition>Creatinine Clearance</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood and urine samples</intervention_name>
    <description>To measure the clearance of creatinine, urea, potassium, magnesium, sodium, chlorine...</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients in intensive care&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dialysis for AKI with minimum 12 hours of continuous renal replacement therapy&#xD;
             (CVVH-CVVHD)&#xD;
&#xD;
          -  Patient in whom dialysis withdrawal is being considered&#xD;
&#xD;
          -  Patients over 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing chronic end-stage renal failure on chronic dialysis&#xD;
&#xD;
          -  Extrarenal purification during hospitalization prior to admission to intensive care&#xD;
             unit&#xD;
&#xD;
          -  Inability to assess the primary outcome&#xD;
&#xD;
          -  Kidney Transplantation&#xD;
&#xD;
          -  Pregnant Women&#xD;
&#xD;
          -  Person not affiliated to a national health insurance&#xD;
&#xD;
          -  Decision to limit or stop therapy&#xD;
&#xD;
          -  Isolated hyperkalemia&#xD;
&#xD;
          -  Refusal of patient participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

